A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer

BACKGROUND: We explored the therapeutic effects of dinaciclib, a cyclin-dependent kinase (CDK) inhibitor, in the treatment of thyroid cancer. MATERIALS AND METHODS: Seven cell lines originating from three pathologic types of thyroid cancer (papillary, follicular and anaplastic) were studied. The cyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Shu-Fu, Lin, Jen-Der, Hsueh, Chuen, Chou, Ting-Chao, Wong, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312924/
https://www.ncbi.nlm.nih.gov/pubmed/28207834
http://dx.doi.org/10.1371/journal.pone.0172315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312924/
https://www.ncbi.nlm.nih.gov/pubmed/28207834
http://dx.doi.org/10.1371/journal.pone.0172315

Ejemplares similares